Vaccitech plc: insider trades · United States · SEC (Form 4)

About Vaccitech plc

Vaccitech plc is a biotechnology company that emerged as a spin-out from the Jenner Institute at the University of Oxford, founded in May 2016. Its scientific founders include Professors Adrian Hill and Sarah Gilbert, both widely associated with infectious-disease vaccinology and viral-vector research. Vaccitech is known for co-inventing a COVID-19 vaccine with the University of Oxford, which was later licensed worldwide to AstraZeneca through Oxford University Innovation. For investors, the company should be viewed as a small-cap clinical biotechnology name that was listed in the United States on the NASDAQ under the ticker VACC, and operated as an international group with cross-border subsidiaries and U.S. reporting obligations. At its core, Vaccitech’s business model has been research-driven rather than commercial. The company focused on the discovery and development of novel immunotherapeutics and vaccines designed to harness T-cell responses against chronic infectious diseases, cancer, and certain autoimmune conditions. Its technology base has been built around viral-vector platforms, which are intended to generate durable immune responses. In practical terms, that means Vaccitech has historically competed as a pipeline company: value creation depended on preclinical and clinical progress, regulatory milestones, and the ability to attract non-dilutive capital or partnership funding. Like many early-stage biotech developers, it did not have a broad, marketed product franchise; instead, it relied on the scientific and clinical potential of its programs. Among its better-known development efforts were programs in chronic hepatitis B and other infectious-disease indications. The company’s positioning in the market has been shaped by this platform-centric approach and by the credibility derived from its Oxford origins. That said, the competitive landscape is intense. Vaccitech has faced competition from large vaccine manufacturers, specialty biotech developers, and other platform companies pursuing similar immunology and infectious-disease opportunities. Its moat has been less about commercial scale and more about scientific know-how, differentiated vectors, and the quality of clinical data generated over time. A major corporate milestone came in 2023, when Vaccitech changed its name to Barinthus Biotherapeutics to better reflect a strategic shift toward T-cell immunotherapy in chronic infectious disease, autoimmunity, and cancer. This is important for investors reviewing historical filings: legacy documents may still refer to Vaccitech plc or its earlier corporate structure, while newer disclosures reflect the Barinthus identity. In other words, the company’s scientific continuity is more important than the branding change. Geographically, Vaccitech was structured as a multinational biotech with subsidiaries in the United Kingdom, the United States, Australia, Italy, and Switzerland. For a French-speaking investor base, the key point is that this was a U.S.-reported NASDAQ-listed name in the United States, even though its scientific and corporate roots were in the UK. The most notable recent developments have centered on the company’s rebranding and continued emphasis on immune-mediated disease programs, reinforcing its profile as a specialized clinical-stage biotech rather than a diversified healthcare platform.